Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 12/20 | 0.58 |
| ▸ | NAMPT | P43490 | 1/20 | 0.55 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.51 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.51 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.51 |
| ▸ | TMPRSS2 | O15393 | 6/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | KDM1A | O60341 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1026165 | 0.82 | HDAC6 (0.64) | HDAC6HDAC8HDAC3HDAC1TMPRSS2 | |
| SCHEMBL3282215 | 0.79 | PRMT5 (0.63) | HDAC6HDAC8HDAC3HDAC1KMT2A | |
| SCHEMBL3282339 | 0.78 | HDAC6 (0.54) | HDAC6HDAC8HDAC3HDAC1NPC1 | |
| SCHEMBL1080738 | 0.77 | HDAC6 (0.67) | HDAC6HDAC8HDAC3HDAC1TMPRSS2 | |
| SCHEMBL7307122 | 0.76 | ITGB3 (0.70) | TMPRSS2RAB9AKMT2A | |
| SCHEMBL3282046 | 0.76 | NAMPT (0.57) | HDAC6NAMPTNPC1RAB9AKMT2A | |
| SCHEMBL1076363 | 0.76 | HDAC6 (0.67) | HDAC6HDAC8HDAC3HDAC1KDM1A | |
| SCHEMBL24891975 | 0.76 | TMPRSS2 (0.80) | TMPRSS2NPC1RAB9A | |
| SCHEMBL1263318 | 0.75 | HDAC6 (0.64) | HDAC6NAMPTHDAC8HDAC3HDAC1 | |
| SCHEMBL12895832 | 0.75 | HDAC6 (0.73) | HDAC6HDAC8HDAC3HDAC1TMPRSS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7705017-B2 | Compounds for treatment of neurodegenerative diseases | EN VIVO PHARMACEUTICALS, INC. (US) | 2010-04-27 | — | — | US | claimed |
| US-20060004041-A1 | Compounds for treatment of neurodegenerative diseases | ENVIVO PHARMACEUTICALS, INC. | 2006-01-05 | — | — | US | claimed |
| WO-2005108367-A1 | COMPOUNDS FOR TREATMENT OF NEURODEGENERATIVE DISEASES | ENVIVO PHARMACEUTICALS, INC. (US) | 2005-11-17 | — | — | WO | claimed |
| US-7705017-B2 | Compounds for treatment of neurodegenerative diseases | EN VIVO PHARMACEUTICALS, INC. (US) | 2010-04-27 | — | — | US | disclosed |
| US-20060004041-A1 | Compounds for treatment of neurodegenerative diseases | ENVIVO PHARMACEUTICALS, INC. | 2006-01-05 | — | — | US | disclosed |
| WO-2005108367-A1 | COMPOUNDS FOR TREATMENT OF NEURODEGENERATIVE DISEASES | ENVIVO PHARMACEUTICALS, INC. (US) | 2005-11-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060004041-A1 | Compounds for treatment of neurodegenerative diseases | HDAC5, HDAC6, HDAC3 | HDAC6 2/4885NAMPT 112/4885HDAC8 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.